In overt diabetic nephropathy (DNP), an increase in the permeability of the glomerular basement membrane (GBM) has been associated with a loss of negatively charged heparan sulfates (HS) in the GBM. Heparanase (HPSE), an endo-b(1-4)-D-glucuronidase, can cleave HS and could be a potential candidate for the degradation of glomerular HS, leading to the development of proteinuria. We analyzed whether changes in HS expression are associated with HPSE expression in overt DNP. Immunofluorescence staining was performed to analyze HS, HPSE, and agrin core protein expression in kidney biopsies from patients with overt DNP and from rats and mice with streptozotocin (STZ)-induced diabetes. We also investigated the effect of transgenic HPSE overexpression in mice on glomerular HS and agrin expression. We demonstrate that the loss of GBM HS (À50%) and tubular HS (À60%) is associated with a four-fold increased HPSE expression in overt DNP. In addition, glomerular HPSE expression is upregulated in rats (messenger RNA (mRNA) 2.5-fold, protein three-fold) and mice (mRNA seven-fold, protein 1.5-fold) with STZ-induced diabetes. Furthermore, transgenic HPSE overexpression results in disappearance of HS, whereas expression of the core protein agrin remains unaltered. Our observations suggest that HPSE is involved in the pathogenesis of proteinuria in overt DNP by degradation of HS.
Diabetic nephropathy (DNP) develops in patients with type I (insulin-dependent) or type II (non-insulin-dependent) diabetes mellitus and is the most common cause of end-stage renal disease in the western world. 1, 2 In the early phase of human DNP, there is a preferential urinary loss of albumin, consistent with a loss of negatively charged heparan sulfates (HS) in the glomerular basement membrane (GBM). Several human and experimental studies have shown that a reduction of glomerular HS was associated with an increased permeability of proteins through the GBM. Heparitinase digestion of glomerular HS resulted in an increased permeability for native albumin and ferritin in rats. 3, 4 Administration of a monoclonal antibody against HS caused massive albuminuria in rats. 5 Importantly, a decrease of HS side chains in the GBM has been described in human DNP, which was inversely correlated with the degree of albuminuria. 6, 7 Finally, treatment with heparin or heparinoids in experimental and human DNP prevented loss of GBM anionic sites and reduced albuminuria. 8, 9 Several mechanisms could lead to the reduction of HS in proteinuric diseases: 10 (1) masking of HS by immune complexes; 11 (2) HS depolymerization by radicals; 12 (3) hyperglycemia-induced reduction of both HS expression and HS sulfation; 13 (4) complement-mediated cleavage of HS; 14 and (5) proteolytic cleavage of the HS attachment site on heparan sulfate proteoglycans by enzymes. 15 We hypothesize that the HS-specific endo-b-D-glucuronidase heparanase (HPSE) can be involved in the degradation of HS in overt DNP. HPSE catalyzes the hydrolytic cleavage of the b(1,4)-glycosidic bond between glucuronic acid and glucosamine residues within HS. 16 HS degradation by HPSE results in the release of many HS-bound molecules including growth factors, extracellular matrix molecules, enzymes, enzyme inhibitors, chemokines, and cytokines, which are involved in processes such as extravasation, growth, and chemotaxis of cells. In addition, cleavage of HS chains leads to disassembly of the basement membranes and facilitates cell migration and invasion of tumor cells into tissues. 16, 17 Besides its role in extracellular matrix degradation, HPSE is also involved in many other biological and pathological processes, such as liver development, embryonic development, cell differentiation, cell growth, morphogenesis, tissue repair, tumor metastasis, angiogenesis, and inflammation. [18] [19] [20] Recent studies revealed that HPSE could be involved in the degradation of HS within the GBM, leading to proteinuria in several (experimental) proteinuric diseases. It has been demonstrated that HPSE activity is increased in the urine of patients with type 1 diabetes. 21, 22 Several experimental studies showed that glomerular HPSE expression was upregulated in rats with puromycin aminonucleoside nephrosis, 23 in passive Heymann nephritis (PHN) 24 and in a model of accelerated anti-GBM disease. 25 Administration of the HPSE inhibitor PI-88 to rats with PHN reduced proteinuria almost two-fold, which was associated with preservation of the amount of HS in the GBM. 26 Transgenic overexpression of HPSE in mice resulted in proteinuria, which was accompanied by effacement of podocyte foot processes. 27 Involvement of glomerular HPSE has also been demonstrated in patients with minimal change disease (Rutjes et al., submitted) and HPSE activity was increased in the urine of children with steroid-sensitive nephrotic syndrome. 28 A recent study demonstrated an upregulation of HPSE in the glomeruli of patients with DNP. Additionally, in vitro data in this study demonstrated that high glucose was able to induce HPSE expression in podocytes, which was associated with a slight reduction of cell surface HS. 29 In this study, we evaluated whether changes in glomerular HS are associated with an increased HPSE expression in overt DNP. We demonstrated a correlation between glomerular HPSE and HS expression in patients with DNP. In streptozotocin (STZ)-induced diabetes in rats and mice, both glomerular HPSE messenger RNA (mRNA) and protein expression were upregulated. Finally, we found that transgenic overexpression of HPSE, leads to loss of glomerular HS expression, whereas the expression of the agrin core protein did not change.
RESULTS

Expression of HPSE in human diabetic nephropathy
Clinical characteristics of the diabetic patients are presented in Table 1 . We evaluated the expression of HS, HPSE, and agrin, by indirect immunofluorescence in kidney biopsies from macroalbuminuric diabetic patients and normal controls ( Figure 1 ). In control kidney sections, a linear staining of the core protein of agrin and HS was observed along the GBM, which fully co-localized ( Figure 1a ). However, in the glomeruli of patients with DNP, a decreased staining of HS along the GBM was observed, whereas the expression of the core protein of agrin in the GBM did not change (Figure 1c ). Glomerular HPSE expression was increased in patients with DNP ( Figure 1d ), whereas in the normal human kidney, only a weak staining of HPSE could be observed (Figure 1b ). In Figure 2 , we present the quantitative analysis of the expression of HS and HPSE. In the glomeruli, HS was significantly decreased in patients with DNP (Po0.001, Figure 2a ), which was associated with an increased HPSE expression (Po0.001, Figure 2b ). A similar change was found in the tubular expression of HS and HPSE (Po0.001, Figure  2c and d). In this study, we found an inverse correlation between GBM HS expression and the degree of proteinuria (Figure 2e ; r ¼ À0.56, Po0.001), which is in line with our previous results. 6 In addition, we observed a correlation between glomerular HS and HPSE expression ( Figure 2f ; r ¼ À0. 29, Po0.05) .
To evaluate the localization of the increased glomerular HPSE expression in diabetic patients, we performed double stainings with HPSE and antibodies against epitopes localized in the GBM (agrin), podocytes (synaptopodin), and mesangial cells (perlecan). Staining of HPSE co-localizes partly with agrin ( Figure 3a ), as well as with synaptopodin ( Figure 3b ), but not with perlecan ( Figure 3c ). The staining along the GBM with agrin reveals the extracellular presence of HPSE, whereas the staining with synaptopodin supports the intracellular localization of HPSE in podocytes. Furthermore, the positive staining of HPSE within some capillary loops suggests that also endothelial cells express HPSE. We do have unpublished data that conditionally immortalized mouse glomerular endothelial cells, 30 and podocytes express HPSE both at the mRNA and protein level.
To define more precisely in which tubular segment HPSE was mainly localized, we performed co-stainings of HPSE with markers for specific segments of the tubular system, that is proximal tubules (P-glycoprotein), distal convoluted tubules (calbindin D-28k), and the collecting ducts (aquaporin-2). As shown in Figure 3d , HPSE expression was mainly localized in the proximal tubules identified with anti-P-glycoprotein in both controls and diabetic patients. HPSE expression did not co-localize with calbindin D-28 k and aquaporin-2 (data not shown).
HPSE expression in rats and mice with STZ-induced diabetes
Five months after the induction of diabetes in rats, we observed an increased staining of glomerular HPSE compared to controls, which was accompanied by a reduction of GBM HS (Figure 4a ). Increased HPSE protein expression in rats with STZ-induced diabetes was confirmed by Western blot analysis. In renal cortex of diabetic rats, the 50 kDa subunit, which is the active form of HPSE, was present, whereas it was undetectable in controls ( Figure 4b ).
Quantification of immunofluorescence stainings showed that HS expression was reduced in diabetic rats. However, loss of HS expression in the GBM did not reach statistical significance ( Figure 4c ). Furthermore, both HPSE protein (immunofluorescence) as well as mRNA expression were significantly increased in diabetic rats compared to controls (Po0.05, Figure 4d ). In diabetic mice, we also observed elevated levels of HPSE mRNA (seven-fold; Po0.01) compared to controls (Figure 5a ). In addition, glomerular HPSE protein expression was also significantly increased (Po0.05, Figure 5b ), although glomerular HS expression was not significantly reduced (P40.05, Figure 5c ). Interestingly, the decrease of HS expression correlated with both the elevated HPSE protein expression ( Figure 5d ; r ¼ À0.82, Po0.05) and HPSE mRNA expression (data not shown; r ¼ À0.72, Po0.05).
Transgenic overexpression of HPSE in mice
To investigate whether overexpression of HPSE is associated with a decrease of glomerular HS expression, we stained kidney sections from mice with transgenic overexpression of HPSE (HPSEtg) with specific antibodies. Overexpression of HPSE was observed in both tubuli and glomeruli of transgenic mice compared to controls, which resulted in an almost complete absence of the expression of HS (Figure 6a ). This underlines the importance of HPSE for HS degradation. Next, we evaluated whether HPSE overexpression affects the expression of the core protein of agrin, to which HS is attached. No differences in expression of the core protein of agrin were observed between HPSEtg mice and controls ( Figure 6a ). Expression of perlecan and collagen IV in HPSEtg mice also remained unchanged (data not shown). In addition, we observed a significant increase in urinary albumin excretion in HPSEtg mice compared to controls (Figure 6b ). To mimic the effect of HPSE overexpression, we applied recombinant active HPSE to normal mouse kidney sections. Similar to the in vivo situation with transgenic overexpression of HPSE, we observed an almost complete disappearance of HS, whereas the expression of the core protein of agrin was unaffected ( Figure 6c ). 
DISCUSSION
We demonstrate that the reduction of HS moieties in the glomeruli of patients with type II diabetes and overt DNP is correlated with an upregulation of HPSE. This association has been suggested previously in studies that describe an increased HPSE expression in experimental models of proteinuria, such as PHN, puromycin aminonucleoside nephropathy, and anti-GBM nephritis. [23] [24] [25] Inhibition of HPSE in PHN by PI-88 reduced proteinuria and partly preserved HS staining, which suggests that HPSE is at least partly responsible for the development of proteinuria. 26 Recently, it has been reported that glomerular HPSE expression was increased in patients with DNP. However, needle biopsies from autopsy specimens were used and renal HS expression was not evaluated. 29 We found a correlation between the loss of HS and the expression of HPSE in the glomeruli, which suggest that HPSE is responsible for the glomerular degradation of HS and, possibly, for the development of proteinuria in overt human DNP. These data are further supported by our observations in the STZ-induced diabetes model (model for type I diabetes) in rats and mice. Both HPSE mRNA and protein expression were increased in diabetic rats and mice, which was associated with a decrease in HS expression. In mice with STZ-induced diabetes, this HS expression was correlated with both HPSE mRNA and protein expression. However, this decrease in HS expression did not reach statistical significance. This is in line with our previous observation in this model using JM403 for HS staining, in which only a relative decrease of HS compared to increased collagen IV content of the GBM was observed. 13, 31 JM403 reacts with free amine groups in glucosamine, 32 and a decrease in N-sulfation (leading to an increased staining) may compensate a decrease in staining owing to a decrease in the amount of HS. This possibility is underlined by our observation that in basement membranes of capillary muscles, an increased staining of JM403 was found in diabetic patients with normo-and microalbuminuria, whereas in patients with macroalbuminuria staining was decreased. 33 Recently, we obtained evidence that in the very early phase of DNP (i.e. microalbuminuria) glomerular HS was not decreased. 34, 35 This was also suggested by a study of Vernier et al., 36 which demonstrated that cuprolinic blue staining in the GBM was not decreased in microalbuminuria, suggesting that decrease of glomerular HS starts in more advanced phases of DNP, as we have found in this study. Previously, we demonstrated that HS expression was decreased in the dermal basement membrane in skin biopsies from patients with DNP. 37 Preliminary data show that HS expression in skin biopsies from diabetic patients normalized after succesful pancreas transplantation, suggesting that changes in HS are reversible if euglycemia is restored.
Glomerular HPSE expression in patients with overt DNP is mainly localized in podocytes and endothelial cells. This is supported by observations that podocytes and endothelial cells are the main cell types that express and release HPSE. 23, 26 It is not clear yet what drives the increased HPSE expression in these cells, but there are some clues which mechanisms may be operative. Recently, it was demonstrated that high glucose was able to increase HPSE expression in podocytes, which was associated with a reduction of cell surface HS. 29 Another possible factor able to induce HPSE expression and activity may be angiotensin II. We have preliminary unpublished data that angiotensin II induces HPSE mRNA expression in cultured mouse podocytes. This is further corroborated by our observation that angiotensinconverting enzyme inhibition in adriamycin nephropathy prevents loss of HS from the GBM 38 and that angiotensin II receptor 1 blockade reduces increased HPSE expression, restores HS loss from the GBM, and reduces proteinuria in the same model. 39 Finally, reactive oxygen species, especially hydroxyl radicals, are involved in the development of proteinuria in adriamycin nephropathy. 12 Recently, we found that besides depolymerization of HS, 12 HPSE was also upregulated in this model, which could be prevented by the hydroxyl scavenger dimethylthiourea. 39 Currently, we are trying to elucidate the mechanisms that could be involved in a disturbed expression of HPSE in overt DNP and other nondiabetic glomerulopathies. HPSE expression was also observed in the cytoplasm of proximal tubules in both controls and diabetic patients. The presence of HPSE in tubuli of normal subjects suggests that HPSE is also involved in the normal physiology of these cells. In diabetic patients, increased urinary HS has been reported. 40, 41 As tubular HPSE expression is increased in diabetic patients, it is possible that the increased urinary excretion of HS originates from tubuli rather than from the glomerulus.
Additionally, we demonstrate that transgenic HPSE overexpression results in a markedly reduced glomerular HS expression, whereas agrin core protein expression remains unchanged. As described previously and confirmed in this study, transgenic overexpression of HPSE resulted in an increased urinary protein excretion, 27 which, along with our findings provides further evidence for a possible involvement of HPSE in the development of proteinuria. The reduction of HS expression in HPSEtg mice was mimicked by treating kidney sections with HPSE, supporting that the decrease of HS was secondary to HPSE overexpression. Very recently, HPSE knockout mice have been generated and induction of diabetes into this model would be interesting to further elucidate the role of HPSE in the pathophysiology of DNP (Dr JP Li, Uppsala, Sweden, personal communication).
We (yet unpublished) and others observed that heparin and several low molecular weight heparins can inhibit the enzymatic activity of HPSE. [42] [43] [44] [45] [46] [47] Both experimental and clinical studies have shown that these heparin(oid)s can reduce proteinuria in both microalbuminuric and macroalbuminuric DNP (reviewed by Gambaro and van der Woude 48 ). In experimental DNP, Gambaro et al. 9 showed that treatment with sulodexide reduced albuminuria, prevented GBM thickening and loss of HS from the GBM. At that time, it was not clear how this beneficial effect was exerted. Sulodexide can inhibit HPSE, so it is conceivable that this explains the renoprotective effect of sulodexide. In addition, the HPSE inhibitor PI-88 was able to reduce proteinuria in PHN nephritis. 26 Unfortunately, these compounds do not only inhibit HPSE activity, but also exert other effects such as anti-coagulant activities. Recently, some well-defined specific HS-based HPSE inhibitors have been developed, but these compounds have a very short half-life of about 4 h, which makes it very difficult to study long-term HPSE inhibition in vivo in experimental DNP (I Vlodavsky; yet unpublished results). Nevertheless, inhibition of HPSE has already been successfully applied in cancer treatment for its anti-metastatic potential. 49 Therefore, it remains to be determined whether inhibition of biological actions of HPSE in vivo with non-coagulant heparinoids is a feasible goal for therapy in DNP.
In conclusion, our data demonstrate that increased glomerular HPSE expression in human and experimental DNP and in mice with transgenic overexpression of HPSE is associated with a decrease of HS in the GBM and albuminuria. These data suggest that increased HPSE expression could be responsible for the decrease of HS in the GBM and the development of proteinuria. The observed anti-proteinuric effects of low molecular weight heparins in DNP underscore this idea. 48 Elucidation of the signals and underlying mechanisms that lead to HPSE overexpression by specific glomerular cell types may provide new clues for the generation of drugs against the development of DNP.
MATERIALS AND METHODS Human renal tissue
We evaluated renal biopsies from 11 patients with overt DNP from patients with type II diabetes mellitus. Control renal tissue was obtained from five non-diabetic individuals, from donor kidneys for anatomical reasons not suitable for transplantation, and from a normal part of kidneys removed for renal adenocarcinoma. Clinical characteristics of the diabetic patients are presented in Table 1 . The Human Ethics Review Committee of the Academic Medical Center Amsterdam approved the analysis of the human kidney biopsies.
Animal models
Rats. Diabetes was induced in male Wistar-Münich rats (n ¼ 4; Jackson Laboratory, Bar Harbor, USA) by intravenous injection of STZ (55 mg/kg body weight). Sex-and age-matched control rats (n ¼ 4) received saline. Blood glucose levels were maintained around B25 mmol/l by treatment with 1.2 IU of bovine insulin (Ultralente; Novo, Copenhagen, Denmark) three times a week. Body weight, blood glucose, urine production, and albuminuria were measured as described previously. 13 Characteristics are listed in Table 2 . Five months after the induction of diabetes, rats were killed and kidneys were processed for analysis.
Mice. C57Bl6/J female mice (n ¼ 6; Harlan, Horst, The Netherlands) were injected intraperitoneally with 200 mg/kg body weight STZ in 10 mM citrate buffer (pH 4.6). Controls (n ¼ 4) received citrate buffer only. Blood glucose levels were measured every 3 days and urine samples were collected at 2, 4, 6, 9, 11, and 13 weeks after induction of diabetes to determine albuminuria as described previously. 50 Slow release insulin pellets (Linshin Canada Inc., Ontario, Canada) were implanted subcutaneously when blood glucose rose above 20 mmol/l. Mice were not ketotic and were killed after 17 weeks of diabetes and tissue samples were processed for analysis. Characteristics are listed in Table 2 .
In addition, kidney tissue was analyzed from transgenic mice, which overexpress HPSE in all tissues. 27 Radial immunodiffusion, as described previously, 51, 52 was used to determine albuminuria in HPSEtg mice (n ¼ 11) and controls (n ¼ 9). Urinary creatinine was measured enzymatically (Roche Diagnostics, Penzberg, Germany) and urinary albumin excretion was expressed as the ratio: mg albumin/mg creatinine. The local Animal Ethical Committees approved the animal experiments.
RNA isolation and real-time reverse transcription-polymerase chain reaction
Total RNA was isolated from rat and mouse kidney tissue using the RNeasy mini-kit (Qiagen Benelux, Venlo, The Netherlands). In rats, mRNA was isolated from purified glomeruli 53 and in mice from renal cortex. One microgram of RNA was reverse transcribed into cDNA using Oligo-dT priming and Superscript reverse transcriptase (Invitrogen Life Technologies, Breda, The Netherlands). HPSE expression was quantified by real-time polymerase chain reaction using iQ TM SYBR s Green Supermix and the MyiQ TM real-time polymerase chain reaction system (Bio-Rad Laboratories, Veenendaal, The Netherlands). Polymerase chain reaction conditions: denaturation at 951C for 3 min, followed by 40 cycles of 951C for 15 s, 571C for 30 s, and 721C for 30 s and finally elongation at 721C for 10 min. Rat primers: HPSE: forward (F) 5 0 -gaagcaaactccgagtgtac-3 0 , reverse (R) 5 0 -ggtttgaccgttcagttgg-3 0 ; RNA polymerase II: (F) 5 0 -gactttgatgacgtggagg-3 0 , (R) 5 0 -ggtcgttcaccagatgggag-3 0 . Mouse primers: HPSE: (F) 5 0 -ggagcaaactccgagtgtatc-3', (R) 5 0 -cagaatttgaccgt tcagttgg-3 0 ; b-actin: (F) 5 0 -gtgggccgctctaggcaccaa-3 0 , (R) 5 0 -ctctttgat gtcacgcacgatttc-3 0 ; RNA polymerase II: (F) 5 0 -caccacgtccaatgatattgtgg-3 0 , (R) 5 0 -gtgctgctgcttccataagg-3 0 (Biolegio BV, Malden, The Netherlands). Expression of the housekeeping genes b-actin and/or RNA polymerase II was used to quantify HPSE expression by the delta-delta cycle time (C t ) method.
Immunofluorescence staining and HPSE treatment of mouse kidney sections
Human DNP. Kidney biopsy sections (5 mm) were fixed in 100% acetone for 10 min at 41C. Sections were incubated with primary antibodies (all listed in Table 3 ) diluted in phosphatebuffered saline (PBS) for 1 h at room temperature, washed twice in PBS, and incubated with the appropriate secondary antibodies diluted in PBS containing 4% normal human serum and 4% normal goat serum for 1 h at room temperature. Subsequently, sections were washed in PBS, embedded in Vectashield mounting medium H-1000 (Vector Laboratories Inc., Burlingame, CA, USA) and examined with confocal laser scanning microscopy (CLSM; Leica, Heidelberg, Germany). At least three glomeruli per section were evaluated by three independent observers. For agrin and HS expression, linearity of the GBM was scored at an arbitrary scale of 0-10 (arbitrary units (a.u.); 0 ¼ no staining, 1 ¼ 10% linear GBM staining, etc., with a maximum score of 10 for 100% linearity) and for HPSE expression, a scale of 0-5 was used for staining intensity. Scoring between the three different observers was consistent, because regression analysis yielded a good correlation for the scores of HS (r 2 ¼ 0.84, r 2 ¼ 0.83, r 2 ¼ 0.84; all Po0.001) and HPSE (r 2 ¼ 0.80, r 2 ¼ 0.74, r 2 ¼ 0.79; all Po0.001).
To investigate which cell type could be responsible for the expression of HPSE in the glomeruli of patients with DNP, immunofluorescence double stainings with HPSE were performed as described above, except that antibodies were diluted in PBS with 1% bovine serum albumin. Synaptopodin was used as a podocyte marker, agrin was used to distinguish between the inside and the outside of the glomerular capillaries, and perlecan was used as a marker for the mesangium. To test in which tubuli from both controls and patients with DNP expression of HPSE was observed, we performed immunofluorescence double stainings with HPSE and a marker for proximal tubuli (P-glycoprotein), a marker for distal convoluted tubuli (calbindin D-28k) or aquaporin 2, which recognizes the collecting duct (Table 3) .
Experimental DNP and HPSE treatment. HS, agrin, and HPSE expression was determined in kidneys of rats and mice with STZinduced diabetes, in kidneys of mice with HPSE overexpression, and in normal mouse kidney tissue after treatment with HPSE. Sections (2 mm) were fixed in 100% acetone for 10 min at 41C. For treatment of normal mouse kidney tissue with active HPSE, unfixed kidney sections were incubated with 0.22 mg/ml active recombinant mouse HPSE 54 for 2 h at 371C in 50 mM sodium acetate buffer (pH 5) after which sections were washed in PBS and fixed for 10 min in 100% acetone at 41C. Staining of HS, HPSE, and the agrin core protein was performed as described above. Normal goat serum (4%) and normal rat serum (4%) were added to the secondary antibodies on rat sections. To detect HS on mouse kidney tissue, we labeled our monoclonal antibody JM403 with digoxigenin (DIG; Roche Diagnostics, Penzberg, Germany). Sections were coded randomly and evaluated by two independent observers as described above.
Western blot analysis
Renal cortex from rats with STZ-induced diabetes and controls was lysed in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% Triton X-100 (Sigma, Zwijndrecht, The Netherlands), and ethylenediaminetetraacetic acid-free protease inhibitors (Roche). Equal amounts of total protein (3 mg; determined with bicinchoninic acid (Sigma)) were incubated overnight at 41C with 100 ml of washed heparin-agarose beads (Sigma). 55 Beads were washed in PBS and then boiled in 100 ml Laemli sample buffer. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed and proteins were transferred to a polyvinylidene difluoride membrane (Bio-Rad). After blocking with 1% Boehringer blocking reagent (Roche) in PBS, HPSE protein was detected by incubation with HPA1 for 1 h (ProsPecTany, 1:700), followed by a 1-h incubation with a peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Heidelberg, Germany, 1:8000). HPSE protein was visualized using a chemiluminescence substrate (Perbio Science, Etten-Leur, The Netherlands) and enhanced chemiluminescence hyperfilm (Amersham Biosciences, Buckinghamshire, UK).
Statistical analysis
Values are expressed as means7s.d. or as medians with ranges when appropriate. Comparison of expression levels between the different groups was evaluated using the non-parametric Mann-Whitney U test. The non-parametric Spearman's rank test was used to calculate correlation between the different variables. A value of Po0.05 was considered significant. We used GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA, USA) for the analysis of our data. 
